Page last updated: 2024-08-25

narciclasine and ER-Negative PR-Negative HER2-Negative Breast Cancer

narciclasine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cao, C; Han, B; Huang, W; Pan, X; Peng, C; Wu, F; Xu, T; Zhang, N	1

Other Studies

1 other study(ies) available for narciclasine and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis. Cell proliferation, 2018, Volume: 51, Issue:6 Topics: Amaryllidaceae Alkaloids; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Line, Tumor; Cell Proliferation; Female; Humans; Intracellular Signaling Peptides and Proteins; Phenanthridines; Triple Negative Breast Neoplasms	2018

Article

Year

Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis.

Cell proliferation, 2018, Volume: 51, Issue:6

Topics: Amaryllidaceae Alkaloids; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Line, Tumor; Cell Proliferation; Female; Humans; Intracellular Signaling Peptides and Proteins; Phenanthridines; Triple Negative Breast Neoplasms

2018